Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo

Yusuf A Haggag1,2, Kyle B Matchett3, Robert A Falconer4

  • 1Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Tanta, Tanta 31111, Egypt. youssif.hagag@pharm.tanta.edu.eg.

Cancers
|February 17, 2019
PubMed

Insights

Novel peptides targeting Ras protein-Regulator of chromosome condensation 1 (Ran) were encapsulated in nanoparticles for cancer therapy. These peptide-loaded nanoparticles demonstrated significant antitumor and anti-metastatic effects in breast and lung cancer models.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Effective delivery of anticancer agents to subcellular targets remains a challenge in cancer therapy.
  • Peptides offer potential as selective, potent therapeutics with low toxicity to normal cells.
  • Ras protein-Regulator of chromosome condensation 1 (Ran) is a novel therapeutic target in breast cancer.

Purpose of the Study:

  • To develop and evaluate novel Ran-inhibitory peptides encapsulated in polyethylene glycol-poly (lactic-co-glycolic acid) (PEG-PLGA) nanoparticles for cancer treatment.
  • To assess the anticancer and anti-metastatic efficacy of these peptide-loaded nanoparticles in vitro and in vivo.

Main Methods:

  • A modified double emulsion solvent evaporation technique was used to create optimized peptide-loaded PEG-PLGA nanoparticles.
  • In vitro studies utilized Ran-expressing breast (MDA-MB-231) and lung (A549) cancer cell lines.
  • In vivo efficacy was evaluated in Solid Ehrlich Carcinoma-bearing mice, alongside migration, invasion, and colony formation assays.

Main Results:

  • PEG-PLGA nanoparticles encapsulating an N-terminal peptide exhibited significant antitumor activity against breast and lung cancer cells in vitro.
  • These nanoparticles demonstrated pronounced anti-metastatic effects in vitro.
  • In vivo studies showed a significant reduction in tumor volume and growth inhibition in a breast cancer model.

Conclusions:

  • Novel Ran-inhibitory peptides effectively delivered via PEG-PLGA nanoparticles show significant potential for cancer therapy.
  • This Ran-targeting peptide construct demonstrates promise for treating breast cancer and other Ran-overexpressing cancers.
  • The developed nanoparticles offer an effective strategy for delivering therapeutic peptides to cancer cells.

Related Concept Videos

Peptide Bonds02:43

Peptide Bonds

A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
82.8K
Self-Efficacy01:29

Self-Efficacy

Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
219
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

Body:Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts.
222
Excitatory and Inhibitory Effects of Neurotransmitters01:29

Excitatory and Inhibitory Effects of Neurotransmitters

When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
12.9K
Impact Loading01:19

Impact Loading

Impact loading occurs when a moving object collides with a stationary structure, such as a rod with a uniform cross-sectional area fixed at one end. Under these conditions, the rod absorbs the kinetic energy from the striking object, leading to deformation and subsequent stress development. As the rod returns to its original position and reaches maximum stress, the absorbed energy, initially manifested as kinetic energy, transforms entirely into strain energy.
In cases of elastic deformation,...
691
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
271